The CAIRP (CAndesartan for In-stent Restenosis Prevention) trial - A multicenter study of AT1-receptor blocker therapy in coronary stenting

Tools

Item Type:	Article
Title:	The CAIRP (CAndesartan for In-stent Restenosis Prevention) trial - A multicenter study of AT1-receptor blocker therapy in coronary stenting
Creators Name:	Kraemer, J., Ruf, R.G., Schmidt, S., Axthelm, C., Strasser, R., Janssen, G., Thieme, T., Kusch, A., Waigand, J., Dietz, R. and Gross, C.M.
Abstract:	Angiotensin II (Ang II) is implicated in the development of in-stent restenosis (ISR). Ang II- and AT1-receptor blockade could possibly reduce ISR. We enrolled 206 patients into a prospective double-blind, placebo-controlled, multicenter randomized trial of candesartan cilexitil 16 mg to test this notion. Mean lumen diameter (MLD) was the primary objective measured by quantitative coronary angiography and intravascular ultrasound. The Candesartan Group showed a trend towards a larger MLD at follow up without significant differences in the binary ISR rate. In vessels < 2.75 mm, we found a larger MLD in the treatment group after 6 months. This might indicate the potential benefit of AT1-receptor blocker therapy for certain subgroups when percutaneous coronary intervention is performed with bare-metal stent implantation.
Keywords:	Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Blood Vessel Prosthesis Implantation, Combined Modality Therapy, Coronary Angiography, Coronary Restenosis, Double-Blind Method, Drug-Eluting Stents, Placebos, Prospective Studies, Tetrazoles, Treatment Outcome
Source:	Journal of Invasive Cardiology
ISSN:	1042-3931
Publisher:	Health Management Publications
Volume:	20
Number:	5
Page Range:	205-210
Date:	May 2008
Official Publication:	http://www.invasivecardiology.com/article/8755
PubMed:	View item in PubMed

Repository Staff Only: item control page